Claire Mathiot

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Gérald Marit et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 899 citations · Full text

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

Hematological Malignancy, Cell Therapy, Transplantation +14